A Single Dose-escalation Study of Cytisine in Adult Smokers
Completed
Achieve Life Sciences
Phase 1
The objectives of this study are:
1. To assess the tolerability and safety of cytisine as a single oral dose.
2. To define the Cmax levels associated to the occurrence of dose-limiting adverse events.
A Study of Cytisinicline for Smoking Cessation in Adult Smokers
Active, not recruiting
Achieve Life Sciences
Phase 3
This placebo-controlled Phase 3 study is being conducted at sites within the United States to
evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks as well as
repeating that duration for a total of 84 days/12 weeks treatment.
A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
Not yet recruiting
Achieve Life Sciences
Phase 3
This placebo-controlled Phase 3 study is being conducted at sites within the United States to
evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks as well as
repeating that duration for a total of 84 days/12 weeks treatment.
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
Not yet recruiting
Achieve Life Sciences
Phase 2
This placebo-controlled Phase 2 study is being conducted at sites within the United States to
evaluate the safety profile of 3 mg cytisinicline administered TID for 12 weeks.
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
Not yet recruiting
Achieve Life Sciences
Phase 1
The primary objective of this trial is to assess the effects of cytisinicline at therapeutic
and supratherapeutic doses on cardiac repolarization relative to placebo in healthy adult
subjects who are smokers.
Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose
Not yet recruiting
Achieve Life Sciences
Phase 1
The primary objectives of this study are:
1. To obtain information on the pharmacokinetics of cytisinicline following a single oral
dose in subjects with varying degrees of renal impairment relative to matched controls
with normal renal function.
2. To investigate the extent of cytisinicline removal by hemodialysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
